Anika Jäkel

Experienced nonclinical and translational biology leader in radiopharmaceutical and immuno-oncology drug development strongly motivated by developing medicines that can make a meaningful difference for patients with severe diseases. I build and lead high-performing teams and drive driving preclinical strategy from target discovery through IND. My focus is on generating high-quality, regulatory-aligned data that inform key portfolio decisions and accelerate development, while effectively coordinating CROs and strategic partners. I am recognized for strong scientific acumen, operational excellence, and a collaborative, solution-oriented leadership style across multidisciplinary and partner environments.